For the readers interested in the stock health of BioNTech SE (BNTX). It is currently valued at $202.35. When the transactions were called off in the previous session, Stock hit the highs of $202.95, after setting-off with the price of $200.80. Company’s stock value dipped to $184.56 during the trading on the day. When the trading was stopped its value was $183.71.
Recently in News on May 11, 2021, Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents. In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years . You can read further details here
BioNTech SE had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $213.15 on 05/04/21, with the lowest value was $83.00 for the same time period, recorded on 01/04/21.
BioNTech SE (BNTX) full year performance was 310.95%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, BioNTech SE shares are logging -5.07% during the 52-week period from high price, and 348.87% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $45.08 and $213.15.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 7152816 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the BioNTech SE (BNTX) recorded performance in the market was 148.22%, having the revenues showcasing 69.33% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 44.69B, as it employees total of 1941 workers.
Analysts verdict on BioNTech SE (BNTX)
During the last month, 4 analysts gave the BioNTech SE a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 118.35, with a change in the price was noted +94.08. In a similar fashion, BioNTech SE posted a movement of +86.89% for the period of last 100 days, recording 2,671,882 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BNTX is recording 0.17 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.17.
BioNTech SE (BNTX): Technical Analysis
Raw Stochastic average of BioNTech SE in the period of last 50 days is set at 91.21%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 87.78%. In the last 20 days, the company’s Stochastic %K was 70.29% and its Stochastic %D was recorded 63.11%.
Let’s take a glance in the erstwhile performances of BioNTech SE, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 148.22%. Additionally, trading for the stock in the period of the last six months notably improved by 119.95%, alongside a boost of 310.95% for the period of the last 12 months. The shares increased approximately by -3.14% in the 7-day charts and went down by 65.67% in the period of the last 30 days. Common stock shares were driven by 69.33% during last recorded quarter.